<DOC>
	<DOCNO>NCT00383214</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Epratuzumab standard treatment patient SLE .</brief_summary>
	<brief_title>Study Epratuzumab Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>+ANA screen BILAG Index B Level Activity least 2 body systems/organs Has SLE ACR revise criterion ( meet , &lt; 4 criterion ) Active Severe Lupus define BILAG Index Level A body system organ . Allergy human antibody Murine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Lupus ,</keyword>
	<keyword>antibody ,</keyword>
	<keyword>B-cell immunotherapy</keyword>
</DOC>